-
Reproductive toxicity studies for biologics: FDA logic
Reproductive toxicity studies for biologics are built around risk questions, not a preset list of tests, with species and endpoints chosen for each drug. The FDA evaluates biologic reproductive risk by first confirming a pharmacologically relevant species, then assigning each unanswered reproductive question to the study and endpoints most able to answer it. Evolocumab shows how a hamster mating study and a monkey repeat-dose study each covered different parts of the same risk chain, instead of repeating one fixed design. Why reproductive toxicity studies for biologics start with species relevance For small molecules, reproductive toxicity testing follows a fairly standard sequence. Fertility and early embryonic development come first, then embryo-fetal…
-
Animal Toxicity in Drug Labels: Why Some Notes Never Warn
An animal toxicity drug label note does not automatically become a warning. Regulators weigh human relevance, the gap between animal and human exposure, and whether clinical data show a matching signal. When the animal hazard is credible but the human case stays weak, the note often settles in section 13.2 of the prescribing information instead of Warnings and Precautions. Why an animal toxicity drug label note is not the same as a warning Most readers open a prescribing information expecting the label to be a clean summary of everything unsafe about a medicine. It is not. Drug labeling is selective by design. The nonclinical file from a full repeat-dose toxicology…